ConductScience.org, home

Paper75339

In-vitro synthesis of anti-acetylcholine-receptor antibody by thymic lymphocytes in myasthenia gravis.

Vincent A and 3 others. Lancet, 1978. Cited by 141 papers, by iCite.

Cite this record

ConductScience Library. In-vitro synthesis of anti-acetylcholine-receptor antibody by thymic lymphocytes in myasthenia gravis. Papers, record 75339. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/75339

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
In-vitro synthesis of anti-acetylcholine-receptor antibody by thymic lymphocytes in myasthenia gravis.
PubMed
Journal
Lancet
PubMed
Year
1978
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
141
iCite
Relative citation ratio, by iCite
3.31
iCite
Revised in PubMed
2019-06-10
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Vincent AA
2Scadding GKG K
3Thomas HCH C
4Newsom-Davis JJ

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AcetylcholineMajor topic
AutoantibodiesMajor topic
Myasthenia GravisMajor topic
T-LymphocytesMajor topic
Thymus GlandMajor topic
Adolescent
Adult
Cells, Cultured
Humans
In Vitro Techniques

Source PubMed

Download CSV of topics

Cited by37

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 141 citations.

PMIDTitleJournalYearIn PapersSource
42427480Pathobiology of thymic epithelial tumours and the treatment strategy based on immuno-oncological characteristics: a narrative review.Mediastinum2026https://conductscience.org/library/papers/42427480PubMed
41981116Morphometric analysis of the thymic epithelial cell network using integrated and orthogonal digital pathology approaches.Commun Biol2026https://conductscience.org/library/papers/41981116PubMed
41164186Thymus research in relation to myasthenia gravis: a new perspective on cell subpopulations and future directions.Front Immunol2025https://conductscience.org/library/papers/41164186PubMed
40889171Distribution of Ectopic Germinal Centers in Thymic Epithelial Tumors and Their Relationship With Thymic Involution.Cancer Sci2025https://conductscience.org/library/papers/40889171PubMed
40666538Thymic hyperplasia in myasthenia gravis: a narrative review.Mediastinum2025https://conductscience.org/library/papers/40666538PubMed
40625741Thymic B cells in aging and autoimmune disease.Front Immunol2025https://conductscience.org/library/papers/40625741PubMed
35942663Novel pathophysiological insights in autoimmune myasthenia gravis.Curr Opin Neurol2022https://conductscience.org/library/papers/35942663PubMed
35389099Seronegative myasthenic crisis: a multicenter analysis.J Neurol2022https://conductscience.org/library/papers/35389099PubMed
35165857Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management.Neurotherapeutics2022https://conductscience.org/library/papers/35165857PubMed
34790201The Multifaceted Roles of B Cells in the Thymus: From Immune Tolerance to Autoimmunity.Front Immunol2021https://conductscience.org/library/papers/34790201PubMed
34071155Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis.Int J Mol Sci2021https://conductscience.org/library/papers/34071155PubMed
33774709Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature.Acta Neuropathol2021https://conductscience.org/library/papers/33774709PubMed
33537838Thymus and autoimmunity.Semin Immunopathol2021https://conductscience.org/library/papers/33537838PubMed
33199596Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis.Proc Natl Acad Sci U S A2020https://conductscience.org/library/papers/33199596PubMed
32547535Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology.Front Immunol2020https://conductscience.org/library/papers/32547535PubMed
31269763Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture.Cells2019https://conductscience.org/library/papers/31269763PubMed
30762205Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.Drugs2019https://conductscience.org/library/papers/30762205PubMed
28940642B cells in the pathophysiology of myasthenia gravis.Muscle Nerve2018https://conductscience.org/library/papers/28940642PubMed
28429039[True thymic hyperplasia : Differential diagnosis of thymic mass lesions in neonates and children].Pathologe2017https://conductscience.org/library/papers/28429039PubMed
26510558Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.Neurotherapeutics2016https://conductscience.org/library/papers/26510558PubMed

See all 37 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/75339

GET https://conductscience.org/api/papers/v1/75339/cited_by?page=2